Screener
Jade Biosciences JBIO Other Income (Expense)
Other Income (Expense) at other companies
Other financials
Where this comes from
Reported directly by Jade Biosciences in its filing.
Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.
The source filing: Jade Biosciences’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:27 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-212088
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Interest income | 3,102 | 615 |
| Change in fair value of Convertible Notes payable(3) | — | (15,400) |
| Other expense | (9) | — |
| Total other income (expense), net | 3,093 | (14,785) |
| Net loss before income tax expense | (40,352) | (38,169) |
| Income tax expense | (16) | — |
| Net loss | $(40,368) | $(38,169) |
| Other comprehensive income (loss): |
Item 1. Financial Statements.
FAQ
- What is Jade Biosciences's other income (expense)?
- Jade Biosciences (JBIO) reported other income (expense) of $3.09M in Q1 2026.
- How has Jade Biosciences's other income (expense) changed year-over-year?
- Jade Biosciences's other income (expense) increased by 120.9% year-over-year, from -$14.79M to $3.09M.
- What is the long-term trend for Jade Biosciences's other income (expense)?
- Over 3 years (2021 to 2024), Jade Biosciences's other income (expense) has grown at a 467.3% compound annual growth rate (CAGR), from $62K to -$11.32M.
- What does other income (expense) mean?
- Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.
Ask your AI about Jade Biosciences's other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude